Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ASN 2026
Effects of finerenone on clinical outcomes by CKD severity: An INFINITY analysis
Finerenone preserved kidney function in a broad CKD population:
Effects on chronic eGFR slope were consistent irrespective of CKD severity
- Heterogeneity was observed for total and acute eGFR slope with less decline in the very high-risk subgroup
Finerenone reduced risks of kidney and CV events irrespective of CKD severity:
Heterogeneity was not observed between CKD subgroups for effects on the composite kidney outcome
- CV risk reduction may have been greater in the low/moderate KDIGO risk category
Finerenone was well tolerated
Treatment-emergent AE rates were similar between finerenone and placebo groups by CKD severity
- Hyperkalemia was more frequent with finerenone, with greater frequency in higher risk groups
Serious hyperkalemia was rare overall
- Hypotension was more frequent with finerenone irrespective of CKD severity
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
